July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Sarah Waliany: Dynamic Debate on 1L Combos vs 1L Osimertinib for EGFR+ NSCLC
Jul 15, 2025, 01:19

Sarah Waliany: Dynamic Debate on 1L Combos vs 1L Osimertinib for EGFR+ NSCLC

Sarah Waliany, Clinical Fellow in Hematology/Oncology at Dana-Farber Cancer Institute, shared a post on X:

“Dynamic debate between Julia Rotow and Benjamin Besse on 1L combos vs 1L Osimertinib for EGFR+ NSCLC

  • FLAURA2 and MARIPOSA more effective for most subgroups than osi alone: highly important for patients with increased risk features
  • Significant tox of MARIPOSA: need for mitigation (subQ ami, COCOON ppx).”

Sarah Waliany: Dynamic Debate on 1L Combos vs 1L Osimertinib for EGFR+ NSCLC

More posts featuring Osimertinib.